Cancer Home > Pomalyst and Breastfeeding
It is unclear if Pomalyst (pomalidomide) passes through breast milk. Women are generally advised to either not take Pomalyst while breastfeeding or to not breastfeed during treatment. Pomalyst is linked to potentially serious side effects, such as low blood cell counts, which could cause complications in a nursing infant. Before using this drug while breastfeeding, discuss the potential risks and benefits with your doctor.
Pomalyst® (pomalidomide) is a prescription medication used to treat people with multiple myeloma whose has cancer has progressed after at least two other treatments. At this time, it is unknown whether Pomalyst passes through breast milk in humans. The manufacturer of the medicine recommends women either stop breastfeeding or stop Pomalyst treatment. If you are currently breastfeeding a child, talk to your healthcare provider prior to taking this medication.
Pomalyst was shown to pass through the breast milk of rats. It has not been studied in breastfeeding women. Therefore, it is unknown whether the medication would also pass through the breast milk of women, or if it would harm a nursing child.
While the lack of information is frustrating, it is important to understand that studies of medications are rarely done in breastfeeding women, as such studies could expose an infant, who would otherwise not benefit from the medication, to possible risks.
Pomalyst can cause potentially serious side effects, including low white blood cell counts, which could lead to infections. Because there is the risk that a nursing infant could be exposed to this drug and could develop serious Pomalyst side effects, it is probably safest to avoid breastfeeding during Pomalyst treatment.